Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Participant (Pediatrics, Adults), By Study Design (Interventional Trials, Observational Trials), By Type (Systemic Edema, Localized Edema), By Region, And S

Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Participant (Pediatrics, Adults), By Study Design (Interventional Trials, Observational Trials), By Type (Systemic Edema, Localized Edema), By Region, And Segment Forecasts, 2023 - 2030

Edema Clinical Trials Market Growth & Trends

The global edema clinical trials market size is expected to reach USD 1.27 billion by 2030, registering a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Several factors driving the growth of the market include the increasing prevalence of edema caused by underlying illnesses such as heart failure, kidney disorders, and liver cirrhosis, increasing expenditures on health care developments in medical research, among others.

In addition, edema research studies are anticipated to fuel the market’s expansion. For instance, in August 2021, Novartis announced encouraging findings from Phase III studies of Beovu treating diabetic macular edema, showing effective outcomes at up to 16-week intervals between doses. The KITE study's results from week 100 of the second year showed that most patients who finished the loading phases and the first 12-week cycle were kept on a 12 or 16-week dosing interval until the study's end.

Edema Clinical Trials Market Report Highlights

• Based on phase, the phase-II segment accounted for the largest revenue share of 35.7% in 2022, as there is more extensive testing in a larger group of patients to assess both efficacy and safety in the phase-II segment. These trials aim to refine the dosage, identify adverse effects, and gather preliminary evidence of the treatment's effectiveness
• The phase-III segment is expected to grow at a CAGR of 5.5% during the forecast period, as it is crucial for obtaining regulatory approval to provide strong evidence of a treatment's effectiveness and safety in a large, diverse patient population
• Based on participant, the adult segment accounted for the largest revenue share of 48.9% in 2022 due to the possibility that they have a more extended history of the condition and a more diverse population regarding its origin and severity
• Based on study design, the interventional trials segment accounted for the largest revenue share of 48.2% in 2022 and is expected to grow at the fastest CAGR of 5.8% over the forecast period. This design takes people from several countries and areas and frequently uses a multicenter technique
• Based on type, the localized edema segment accounted for the largest revenue share of 63.5% in 2022. The frequency and intensity of localized edema in some populations would increase its significance in clinical trials for particular geographic areas or healthcare settings
• In 2022, North America dominated the market with a revenue share of 41.4% as it consists of academic institutions, research facilities, and places for clinical trials. It also offers an advanced and robust research infrastructure. Asia Pacific is anticipated to grow at the fastest CAGR of 6.1% over the forecast period, with countries such as China and India serving as significant centers for pharmaceutical production and research

Please note The report will be delivered in 2-3 business days upon order notification.